Publication: Salvage Therapy with CeftolozaneTazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections
Loading...
Identifiers
Date
2016-12-08
Authors
Jose Caston, Juan
De la Torre, Alvaro
Ruiz-Camps, Isabel
Luisa Sorli, Maria
Torres, Vicente
Torre-Cisneros, Julian
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
American Society for Microbiology
Metrics
Export
Abstract
Infections caused by multidrug-resistant Pseudomonas aeruginosa (MDRPA) present a major problem for therapeutic management. We report here our experience with 12 patients with a severe MDRPA infection (6 of which were pneumonia) who received salvage therapy with ceftolozane-tazobactam after inappropriate empirical treatment and/or suboptimal targeted treatment. Although 10 of the 12 patients (83.3%) experienced septic shock, only 3 patients (25%) died during the follow-up period. Microbiological cure in 7 patients (58.3%) was observed.
Description
MeSH Terms
Urinary-tract-infections
Double-blind
Ceftolozane/tazobactam
Double-blind
Ceftolozane/tazobactam
DeCS Terms
Infecciones urinarias
Tazobactam
Tazobactam
CIE Terms
Keywords
Pseudomonas aeruginosa, Salvage therapy, Ceftolozane-tazobactam
Citation
Castón JJ, De la Torre Á, Ruiz-Camps I, Sorlí ML, Torres V, Torre-Cisneros J. Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections. Antimicrob Agents Chemother. 2017 Feb 23;61(3):e02136-16